(Q46310697)

21 December 2017

title

Minimization of immunosuppression: transplant immunology (English)

1 reference

21 December 2017

1 reference

0 references

2

Jon A Kobashigawa

1 reference

21 December 2017

author name string

Jignesh Patel

series ordinal

1

1 reference

21 December 2017

publication date

16 October 2008

1 reference

21 December 2017

published in

Transplant Immunology

1 reference

21 December 2017

volume

20

1 reference

21 December 2017

issue

1-2

1 reference

21 December 2017

page(s)

48-54

1 reference

21 December 2017

Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Neoral versus Sandimmun: clinical impact and modification of immunosuppressive therapy in cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Long-term safety and efficacy of Neoral in heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Tacrolimus in heart transplant recipients: an overview.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Outcome of heart transplants 15 to 20 years ago: graft survival, post-transplant morbidity, and risk factors for mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

The need for a tailored immunosuppression in older heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Early screening for antibody-mediated rejection in heart transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Cardiac transplantation with corticosteroid-free immunosuppression: Long-term result

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Chronic renal failure after transplantation of a nonrenal organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients--the IMPROVED multi-centre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Use of mycophenolate mofetil in patients with transplanted heart and renal insufficiency: the relevance of the pharmacokinetic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Late reduction in cyclosporine dosage does not improve renal function in pediatric heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Mycophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Tacrolimus monotherapy in adult cardiac transplant recipients: intermediate-term results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Long-term results of tacrolimus monotherapy in cardiac transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Randomized trial of tacrolimus monotherapy: tacrolimus in combination, tacrolimus alone compared (the TICTAC trial).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Use of an immune function assay to monitor immunosuppression for treatment of post-transplant lymphoproliferative disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.10.001

10.1016/J.TRIM.2008.10.001

7 January 2021

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017